CA3246092A1 - CRYSTALLINE FORMS OF AN MCL-1 INHIBITOR - Google Patents

CRYSTALLINE FORMS OF AN MCL-1 INHIBITOR

Info

Publication number
CA3246092A1
CA3246092A1 CA3246092A CA3246092A CA3246092A1 CA 3246092 A1 CA3246092 A1 CA 3246092A1 CA 3246092 A CA3246092 A CA 3246092A CA 3246092 A CA3246092 A CA 3246092A CA 3246092 A1 CA3246092 A1 CA 3246092A1
Authority
CA
Canada
Prior art keywords
crystalline form
radiation
amg
xrpd pattern
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246092A
Other languages
English (en)
French (fr)
Inventor
Ron C. KELLY
Mary CHAVES
Jing Teng
Stephan Parent
Markian Stec
Van Luu
Robert P. Farrell
James E. HUCKLE
Michal ACHMATOWICZ
Tian Wu
Darren L. REID
Lingyun XIAO
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3246092A1 publication Critical patent/CA3246092A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3246092A 2022-02-04 2023-02-03 CRYSTALLINE FORMS OF AN MCL-1 INHIBITOR Pending CA3246092A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306776P 2022-02-04 2022-02-04
US63/306,776 2022-02-04
PCT/US2023/012251 WO2023150249A1 (en) 2022-02-04 2023-02-03 Crystalline forms of an mcl-1 inhibitor

Publications (1)

Publication Number Publication Date
CA3246092A1 true CA3246092A1 (en) 2023-08-10

Family

ID=85570021

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246092A Pending CA3246092A1 (en) 2022-02-04 2023-02-03 CRYSTALLINE FORMS OF AN MCL-1 INHIBITOR

Country Status (7)

Country Link
US (1) US20250115622A1 (enExample)
EP (1) EP4472984A1 (enExample)
JP (1) JP2025505141A (enExample)
AU (1) AU2023216691A1 (enExample)
CA (1) CA3246092A1 (enExample)
MX (1) MX2024009448A (enExample)
WO (1) WO2023150249A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519271A1 (en) 2022-05-04 2025-03-12 Gilead Sciences, Inc. Salts and polymorphs of certain mcl-1 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
JP2021161114A (ja) * 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化

Also Published As

Publication number Publication date
JP2025505141A (ja) 2025-02-21
US20250115622A1 (en) 2025-04-10
EP4472984A1 (en) 2024-12-11
MX2024009448A (es) 2024-08-15
AU2023216691A1 (en) 2024-07-04
WO2023150249A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
JP5692873B2 (ja) ジアミン誘導体の結晶およびその製造方法
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
US20250115622A1 (en) Crystalline Forms Of An MCL-1 Inhibitor
US20240140966A1 (en) Amorphous and crystalline forms of mcl-1 antagonists
US20250122224A1 (en) Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397)
US12351588B2 (en) Salt forms and solvates of Mcl-1 antagonists
US12612405B2 (en) Crystalline form of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-a]pyrazin-4-Yl)-Nmethylazetidin-3-amine hydrogen sulfate monohydrate
EP4177257A1 (en) Succinate of octahydrothienoquinoline compound, and crystals thereof
EP4553078A1 (en) 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof
US20260103466A1 (en) Process for the manufacture of salts and crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-nmethylazetidin-3-amine and novel crystalline forms
EP4349835A1 (en) Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof
EP4594322A1 (en) Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine mono succinate
TW202428578A (zh) １－（８－溴化吡啶并［２，３－ｅ］［１，２，４］三唑并［４，３－ａ］吡嗪－４－基）－ｎ－甲基吖丁啶－３－胺之新穎結晶型

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240703

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241022

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241022

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241022

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241024

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241119

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260122